Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 9014
© 2004 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schlemmer, M. Articles by Issels, R. D. Search for Related Content PubMed Articles by Schlemmer, M. Articles by Issels, R. D.

Abstract

Efficacy of consolidation high-dose chemotherapy (HDCT) with ifosfamide, carboplatin and etoposide followed by peripheral blood stem cell rescue (PBSCR) in chemosensitive patients with metastatic soft tissue sarcomas

Klinikum Grosshadern, Muenchen, Germany

9014

Background: Prognosis of patients (pts) with metastatic soft tissue sarcomas (STS) is poor even after an objective clinical response to intensive doxorubicin based chemotherapy (response rate (RR) 23–45 %, median survival 13–15 months). Whether HDCT and PBSCR improves these results is an open question. We report phase II data of response to AI-G chemotherapy regime in pts with metastatic STS and the efficacy of HDCT and PBSCT. Patients and methods: From 1997 to 2003, 55 pts with metastatic STS were prospectively treated with 4 cycles of AI-G (adriamycin 75mg/m2, ifosfamide 6g/m2 with G-CSF support) as induction chemotherapy. After assessment of response pts with CR or PR received 2 further cycles AI-G with collection of peripheral blood stem cells (PBSCs). HDCT consisted of ifosfamide (12g/m2), etoposide (1,2g/m2) and carboplatin (1,2g/m2) (HD-ICE) followed by reinfusion of PBSCs. Results: Of 55 pts 20 pts (RR 36%) were assessed as responders (3CR;17PR) and all but two pts, who refused, received HDCT with PBSCR. The 18 pts receiving HD-ICE experienced grade IV hematologic toxicity while no severe infectious complications were observed and no toxic death occured. By intent to treat analysis (20 pts) the 2-year and 5-year-overall survival (OS) are 50% and 26 %, the median survival is 23 months (median follow-up 21 months). Of nine pts being alive four pts are alive with NED at 11+, 22+, 42+,79+ months and five pts are alive with disease at 11+, 14+, 17+, 31+, 37+ months. 11 pts have died. Conclusion: Survival of pts with chemosensitive metastatic STS seems to be significantly prolonged by HDCT and PBSCR.

No significant financial relationships to disclose.

Abstract presentation from the 2004 ASCO Annual Meeting